A practical reference on HGF/c-Met: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-12 and is reviewed periodically as new material appears.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
| Property | Value | Notes |
|---|---|---|
| Primary proposed target | HGF/c-Met signaling | Direct binding not confirmed |
| Research models | Rodent and cell studies | Preclinical only |
| Human clinical data | None published | Safety and efficacy unknown |
| Regulatory status | Unapproved research chemical | Status varies by country |
| Typical research purity | 95% or higher by HPLC | Depends on supplier and batch |
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
In 1882, he was appointed professor of chemistry at the University of Erlangen and in 1885 at the University of Würzburg. In 1892, he succeeded von Hofmann as professor of chemistry at the Friedrich Wilhelm University of Berlin.
Oxycodone has a hydroxy group at carbon-14 (codeine has just a hydrogen in its place) Oxycodone has a 7,8-dihydro feature. Codeine has a double bond between those two carbons; and Oxycodone has a carbonyl group (as in ketones) in place of the hydroxyl group of codeine. It is also similar to hydrocodone, differing only in that it has a hydroxyl group at carbon-14.
Omacetaxine mepesuccinate (INN; trade name Synribo; formerly named as homoharringtonine or HHT) is a pharmaceutical drug substance that is indicated for treatment of chronic myeloid leukemia (CML). Omacetaxine approval in US is discontinued (August 2024)[1][2] and is no longer recommended for treatment of CML (as of NCCN CML guidance 3.2025) [3]. HHT is a natural plant alkaloid derived from Cephalotaxus fortunei. HHT and related compound esters of cephalotaxine were described first in 1970, and were the subject of intensive research efforts by Chinese investigators to clarify their role as anticancer and antileukemic agents from the 1970s until the present. It was approved by the US FDA in October 2012 for the treatment of adult patients with CML with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKIs).
Sources: en.wikipedia.org
Another GT31 Clade 10 member, named GALT31A, encodes a β-1,6-GalT when heterologously expressed in E. coli and Nicotiana benthamiana and elongated β-1,6-galactan side chains of AGP glycans. GALT29A, a member of GT29 family was identified as being co-expressed with GALT31A and act co-operatively and form complexes. Three members of GT14 named GlcAT14A, GlcAT14B, and GlcAT14C were reported to add GlcA to both β-1,6- and β-1,3-Gal chains in an in vitro enzyme assay following heterologous expression in Pichia pastoris. Two α-fucosyltransferase genes, FUT4 and FUT6, both belonging to GT37 family, encode enzymes which add α-1,2-fucose residues to AGPs. They appear to be partially redundant as they display somewhat different AGP substrate specificities. A GT77 family member, REDUCED ARABINOSE YARIV (RAY1), was found to be a β-arabinosyltransferase that adds a β-Araf to methyl β-Gal of a Yariv-precipitable wall polymer. More research is expected to functionally identify other genes involved in AGP glycosylation and their interactions with other plant cell wall components.
External costs, including those associated with remediation of soil and water contamination, treatment of related diseases, and monitoring of pollution, may be as high as US$17.5 trillion annually, according to ChemSec. PFAS have been a subject of multiple lawsuits worldwide. In the United States, settlements stemming from PFAS pollution claims have reached $18 billion by 2024. In 2023, Sweden's Supreme Court set a legal precedent by awarding damages to citizens who were supplied PFAS contaminated drinking water. Countries such as Canada have published drinking water guidelines for PFOS and PFOA The European Union is developing an action plan to eliminate non-essential uses of PFAS. The United Nations has listed PFOS, PFOA, PFHxS, long-chain PFCAs and related chemicals as persistent organic pollutants under the Stockholm Convention on Persistent Organic Pollutants between 2009 and 2025. The United States Environmental Protection Agency has published non-enforceable drinking water health advisories for PFOA and PFOS. In 2021, Maine became the first U.S. state to ban these compounds in all products by 2030. As of October 2020, the states of California, Connecticut, Massachusetts, Michigan, Minnesota, New Hampshire, New Jersey, New York, Vermont, and Wisconsin had enforceable drinking water standards for between two and six types of PFAS. However, some major producers and users such as the United States, Israel, and Malaysia have not ratified the agreement on reducing use of PFAS, and the chemical industry has lobbied governments to reduce regulations.
== Last Universal Common Ancestor (LUCA) == Some authors equate models of the origin of life with LUCA, the Last Universal Common Ancestor of all extant life. This is a serious error resulting from failure to recognize that L refers to the last common ancestor, not to the first ancestor, which is much older: a large amount of evolution occurred before the appearance of LUCA. Gill and Forterre expressed the essential point as follows:
=== Conformation === The secondary structure of intact and PEGylated lysozyme can be characterized by circular dichroism (CD) spectroscopy. The CD spectra range from 189 - 260 nm with a pitch of 0.1 nm showed no significant change in the secondary structure of the intact and PEGylated lysozyme.
Sources: en.wikipedia.org
== Selected publications == Bence, Kendra K.; Delibegovic, Mirela; Xue, Bingzhong; Gorgun, Cem Z.; Hotamisligil, Gokhan S.; Neel, Benjamin G.; Kahn, Barbara B. (2006). "Neuronal PTP1B regulates body weight, adiposity and leptin action". Nature Medicine. 12 (8): 917–924. doi:10.1038/nm1435. ISSN 1546-170X. PMID 16845389. S2CID 10654045. Delibegovic, Mirela; Zimmer, Derek; Kauffman, Caitlin; Rak, Kimberly; Hong, Eun-Gyoung; Cho, You-Ree; Kim, Jason K.; Kahn, Barbara B.; Neel, Benjamin G.; Bence, Kendra K. (2009-03-01). "Liver-Specific Deletion of Protein-Tyrosine Phosphatase 1B (PTP1B) Improves Metabolic Syndrome and Attenuates Diet-Induced Endoplasmic Reticulum Stress". Diabetes. 58 (3): 590–599. doi:10.2337/db08-0913. ISSN 0012-1797. PMC 2646057. PMID 19074988. Delibegovic, Mirela; Bence, Kendra K.; Mody, Nimesh; Hong, Eun-Gyoung; Ko, Hwi Jin; Kim, Jason K.; Kahn, Barbara B.; Neel, Benjamin G. (2007-11-01). "Improved Glucose Homeostasis in Mice with Muscle-Specific Deletion of Protein-Tyrosine Phosphatase 1B". Molecular and Cellular Biology. 27 (21): 7727–7734. doi:10.1128/MCB.00959-07. ISSN 0270-7306. PMC 2169063. PMID 17724080.
Copurification in a chemical or biochemical context is the physical separation by chromatography or other purification technique of two or more substances of interest from other contaminating substances. For substances to co-purify usually implies that these substances attract each other to form a non-covalent complex such as in a protein complex. However, when fractionating mixtures, especially mixtures containing large numbers of components (for example a cell lysate), it is possible by chance that some components may copurify even though they don't form complexes. In this context the term copurification is sometimes used to denote when two biochemical activities or some other property are isolated together after purification but it is not certain if the sample has been purified to homogeneity (i.e., contains only one molecular species or one molecular complex). Hence these activities or properties are likely but not guaranteed to reside on the same molecule or in the same molecular complex.
In light of these events, Rush's record label tried to pressure the members into moulding their next album in a more commercially friendly and accessible fashion; the band ignored the requests and developed their next album 2112 (1976) with a 20-minute title track divided into seven sections. Despite that, the album was the Rush's first taste of significant commercial success as it reached No. 5 in Canada, becoming their first to reach double platinum certification. Rush toured in support of 2112 between February 1976 and June 1977 with concerts in Canada, the US, and for the first time Europe, with dates in the UK, Sweden, Germany, and the Netherlands. The three sold-out shows at Massey Hall in Toronto in June 1976 were recorded for Rush's debut live album, All the World's a Stage. Released in September of that year, the double album reached No. 6 in Canada and became Rush's first to crack the US top 40. Record World wrote: "Building its American reputation slowly but steadily Rush stands poised for breaking through all the way via this two record live set [...] All the highly charged electricity is here in an explosive setting." The liner notes include the statement, "This album to us, signifies the end of the beginning, a milestone to mark the close of chapter one, in the annals of Rush."
He concluded by declaring anarchy to be the best form of political regime, as it was law that gave rise to tyranny and anarchic revolution that was capable of bringing down bad governments. After the American Revolution, Thomas Jefferson suggested that a stateless society might lead to greater happiness for humankind and has been attributed the maxim "that government is best which governs least". Jefferson's political philosophy later inspired the development of individualist anarchism in the United States, with contemporary right-libertarians proposing that private property could be used to guarantee anarchy.
Root: It is the attached part, consisting of the bulb in the middle and the crura, one crus on either side of the bulb. It lies within the superficial perineal pouch. The crus is attached to the pubic arch. Shaft: The pendulous part of the penis. It has two surfaces: dorsal (posterosuperior in the erect penis) and ventral or urethral (facing downwards and backwards on the flaccid penis). The ventral surface is marked by the penile raphe. The base of the shaft is supported by the suspensory ligament, which is attached to the pubic symphysis. Epithelium of the penis consists of the shaft skin, the foreskin (prepuce), and the preputial mucosa on the inside of it. The foreskin covers and protects the glans and shaft. The epithelium is not attached to the underlying shaft, so it is free to glide to and fro. The human penis is made up of three columns of erectile tissue: two corpora cavernosa lie next to each other (separated by a fibrous septum) on the dorsal side and one corpus spongiosum lies between them on the ventral side. These columns are surrounded by a fibrous layer of connective tissue called the tunica albuginea. The corpora cavernosa are innervated by lesser and greater cavernous nerves and form most of the penis containing blood vessels that fill with blood to help make an erection. The crura are the proximal parts of the corpora cavernosa. The corpus spongiosum is an erectile tissue surrounding the urethra. The proximal parts of the corpus spongiosum form the bulb and the distal ends form the glans penis.
Sources: en.wikipedia.org
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.
No published human clinical trials are available for dihexa. Its safety and effectiveness in people are therefore unknown. Most available evidence comes from animal and cell studies.
Preclinical studies often measure dendritic spine density and synaptic protein levels. Behavioral tests include maze learning and avoidance tasks. These endpoints are indirect and do not establish clinical benefit.
Liquid chromatography–mass spectrometry is commonly used. It provides molecular mass and purity information. Other methods may include HPLC with ultraviolet detection.